Bayer AG reported adjusted first-quarter earnings of €4.45 billion ($5.2 billion) before interest, taxes, depreciation, and amortization, surpassing the €3.9 billion consensus forecast from a Bloomberg survey of analysts. This robust performance was largely attributed to its Crop Science unit, leading to a rise in Bayer's shares.
The Crop Science division's strong growth was primarily fueled by its soybean seed and traits business, with sales doubling due to a €448 million licensing payment related to a seed-technology dispute. The re-approval of the soy crop herbicide Dicamba also contributed to price recovery. JPMorgan analysts, including Richard Vosser, noted the "strong" results and better-than-expected profitability in both pharmaceutical and crop-science segments, highlighting an anticipated weaker currency-related headwind.
Despite the overall positive results, the crop-protection business experienced declining sales. Bayer has been implementing an efficiency program to improve the Crop Science unit's margins, which includes divesting less-profitable products. Markus Manns, a portfolio manager at Union Investment, commented that the "turnaround has taken hold, and the period of repeated disappointments and profit warnings appears to be over."
Bayer also confirmed its full-year outlook on a currency-adjusted basis, stating that the Middle East conflict has no material impact on its guidance currently. The company remains vigilant for potential increases in energy, raw materials, and logistics costs, ready to implement countermeasures if necessary. Beyond operational performance, Bayer is closely monitoring a U.S. Supreme Court decision on Roundup claims, with CEO Bill Anderson stating the company is prepared for all outcomes and believes it can significantly manage litigation this year.
